This site uses cookies to provide you with a more responsive and personalized service. By using this site you agree to our use of cookies. Please read our cookie notice for more information on the cookies we use and how to delete or block them.

Bookmark Email Print this page

Mitigating Global Fraud and Corruption Risks in Life Sciences R&D


This article highlights the risks associated with third-party relationships and vulnerabilities along the R&D chain, including pre-clinical research, pre-trial preparation, patient recruitment and informed consent, product prototype development, data gathering and results analysis and protection from infringement on marketed products. It also outlines steps to help life sciences companies mitigate R&D fraud and corruption risks, including conducting appropriate due diligence, monitoring CROs, CMOs and other third-party business providers, analyzing physician payments, collaboration between R&D and compliance groups and designing proactive and predictive analyses. 

Related links

Share this page

Email this Send to LinkedIn Send to Facebook Tweet this More sharing options

Stay connected